Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

NCT06610643 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
SARS-CoV-2
Immunocompromised

Interventions

DRUG: combination therapy
DRUG: SOC

Sponsor

National Taiwan University Hospital